Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial

被引：0
|
作者：
Tetsu Hayashida
Hiromitsu Jinno
Katsuaki Mori
Hiroki Sato
Akira Matsui
Takashi Sakurai
Hiroaki Hattori
Shin Takayama
Masahiro Wada
Maiko Takahashi
Hirohito Seki
Tomoko Seki
Aiko Nagayama
Akiko Matsumoto
Yuko Kitagawa
机构：
[1] Keio University School of Medicine,Department of Surgery
[2] Teikyo University School of Medicine,Department of Surgery
[3] Hino Municipal Hospital,Department of Surgery
[4] Mito Red Cross Hospital,Department of Surgery
[5] National Hospital Organization Tokyo Medical Center,Department of Surgery
[6] JCHO Saitama Medical Center,Division of Surgery
[7] Federation of National Public Service Personnel Mutual Aid Associations,Department of Surgery
[8] Tachikawa Hospital,Department of surgery
[9] Tokyo Dental College Ichikawa General Hospital,Department of Surgery
[10] Sanokousei general hospital,undefined
来源：
BMC Cancer | / 18卷
关键词：
Breast cancer; Eribulin; Phase II trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [11] Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies
    O'Shaughnessy, Joyce
    McIntyre, Kristi
    Schwartzberg, Lee
    Wilks, Sharon
    Puhalla, Shannon
    Berrak, Erhan
    Song, James
    Vahdat, Linda
    SPRINGERPLUS, 2015, 4
  • [12] A Single-Arm Phase II Trial of First-Line Paclitaxel in Combination with Lapatinib in HER2-Overexpressing Metastatic Breast Cancer
    Jagiello-Gruszfeld, Agnieszka
    Tjulandin, Sergei
    Dobrovolskaya, Natalya
    Manikhas, Alexey
    Pienkowski, Tadeusz
    DeSilvio, Michelle
    Ridderheim, Mona
    Abbey, Rowena
    ONCOLOGY, 2010, 79 (1-2) : 129 - 135
  • [13] Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial
    U. O. Njiaju
    A. J. Tevaarwerk
    K. Kim
    J. E. Chang
    R. M. Hansen
    T. L. Champeny
    A. M. Traynor
    S. Meadows
    L. Van Ummersen
    K. Powers
    J. A. Stewart
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 613 - 618
  • [14] Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)
    Rochlitz, C.
    Ruhstaller, T.
    Lerch, S.
    Spirig, C.
    Huober, J.
    Suter, T.
    Buehlmann, M.
    Fehr, M.
    Schoenenberger, A.
    von Moos, R.
    Winterhalder, R.
    Rauch, D.
    Mueller, A.
    Mannhart-Harms, M.
    Herrmann, R.
    Cliffe, B.
    Mayer, M.
    Zaman, K.
    ANNALS OF ONCOLOGY, 2011, 22 (01) : 80 - 85
  • [15] Multicenter Phase II Study with Weekly Bendamustine and Paclitaxel as First- or Later-Line Therapy in Patients with Metastatic Breast Cancer: RiTa II Trial
    Loibl, Sibylle
    Doering, Gabriele
    Mueller, Lothar
    Grote-Metke, Albert
    Mueller, Roberto
    Tome, Oliver
    Wiest, Wolfgang
    Maisch, Andrea
    Nekljudova, Valentina
    von Minckwitz, Gunter
    BREAST CARE, 2011, 6 (06) : 457 - 461
  • [16] Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea
    Tremblay, Gabriel
    Majethia, Unnati
    Breeze, Janis L.
    Kontoudis, Ilias
    Park, Jeongae
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2016, 8 : 485 - 493
  • [17] CapOX as neoadjuvant chemotherapy for locally advanced operable colon cancer patients: a prospective single-arm phase II trial
    Liu, Fangqi
    Yang, Li
    Wu, Yuchen
    Li, Cong
    Zhao, Jiang
    Keranmu, Adili
    Zheng, Hongtu
    Huang, Dan
    Wang, Lei
    Tong, Tong
    Xu, Junyan
    Zhu, Ji
    Cai, Sanjun
    Xu, Ye
    CHINESE JOURNAL OF CANCER RESEARCH, 2016, 28 (06) : 589 - 597
  • [18] Results of a phase II trial with cystemustine at 90 mg/m2 as a first- or second-line treatment in advanced malignant melanoma:: a trial of the EORTC Clinical Studies Group
    Cure, H
    Souteyrand, P
    Ouabdesselam, R
    Roche, H
    Ravaud, A
    D'incan, M
    Viens, P
    Fargeot, P
    Lentz, MA
    Fumoleau, P
    Hanauske, A
    Chollet, P
    MELANOMA RESEARCH, 1999, 9 (06) : 607 - 610
  • [19] Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial
    Javier Cortes
    Stacie Hudgens
    Chris Twelves
    Edith A. Perez
    Ahmad Awada
    Louise Yelle
    Susan McCutcheon
    Peter A. Kaufman
    Anna Forsythe
    Galina Velikova
    Breast Cancer Research and Treatment, 2015, 154 : 509 - 520
  • [20] Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)
    Kenjiro Aogi
    Kenichi Watanabe
    Masahiro Kitada
    Takafumi Sangai
    Shoichiro Ohtani
    Tomoyuki Aruga
    Hidetoshi Kawaguchi
    Tomomi Fujisawa
    Shigeto Maeda
    Takashi Morimoto
    Nobuaki Sato
    Shintaro Takao
    Satoshi Morita
    Norikazu Masuda
    Masakazu Toi
    Shinji Ohno
    International Journal of Clinical Oncology, 2021, 26 : 1229 - 1236
12345